ALVO

Peers: TEVA AMRX OGN RDY EVO VTRS AMPH ANIP AMGN PFE

| Held by: IBB IDNA EWX PRFZ IBBQ GLCR BIB KBFR

Index	-
Market Cap	1.77B
Enterprise Value	3.08B
Income	-179.59M
Sales	491.95M
Book/sh	-0.54
Cash/sh	0.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1460
IPO	Nov 09, 2020

P/E	-
Forward P/E	19.65
PEG	-
P/S	3.60
P/B	-
P/C	12.39
P/FCF	-
EV/EBITDA	35.71
EV/Sales	6.26
Quick Ratio	0.96
Current Ratio	1.65
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.56
EPS next Y	0.23
EPS next Q	-0.02
EPS this Y	86.60%
EPS next Y	1820.75%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	91.85% -
EPS Y/Y TTM	-365.51%
Sales Y/Y TTM	-12.17%
EPS Q/Q	-276.37%
Sales Q/Q	-38.94%
Earnings	Nov 11 AMC
EPS/Sales Surpr.	-62.17% 2.91%

Insider Own	55.53%
Insider Trans	0.00%
Inst Own	11.08%
Inst Trans	8.17%
ROA	-12.05%
ROE	-
ROIC	-14.88%
Gross Margin	60.45%
Oper. Margin	9.12%
Profit Margin	-36.51%
SMA20	-11.89%
SMA50	-14.80%
SMA200	7.68%
Trades

Shs Outstand	356.82M
Shs Float	173.61M
Short Float	3.67%
Short Ratio	6.03
Short Interest	6.36M
52W High	7.81 -42.00%
52W Low	2.94 54.08%
Volatility	4.26% 5.21%
ATR (14)	0.27
RSI (14)	36.79
Beta	0.24
Rel Volume	0.94
Avg Volume	1.06M
Volume	672,048

Perf Week	-1.95%
Perf Month	-16.88%
Perf Quarter	17.97%
Perf Half Y	28.69%
Perf YTD	-11.70%
Perf Year	-40.78%
Perf 3Y	-49.10%
Perf 5Y	-54.24%
Perf 10Y	-
Recom	1.38
Target Price	7.27
Prev Close	4.65
Price	4.53
Change %	-2.58%

Consensus

Strong Buy

Avg. Price Target

$7.27

Implied Upside

+60.5%

Analysts7incl. previous ratings

Rating Distribution5 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 16, 2026	Upgrade	BBarclays	Underweight → Overweight	$8	+76.6%
Aug 24, 2026	Initiated	BBofA Securities	Buy	$7	+54.5%
Aug 14, 2026	Initiated	EEvercore ISI	Outperform
Dec 09, 2025	Initiated	BBarclays	Underweight	$5	+10.4%
Nov 04, 2025	Downgrade	DDeutsche Bank	Buy → Hold	$8	+76.6%
Oct 14, 2025	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$14	+209.1%
Sep 23, 2025	Upgrade	DDeutsche Bank	Hold → Buy	$14	+209.1%
Feb 14, 2025	Initiated	UUBS	Buy	$18	+297.4%
Jan 29, 2024	Upgrade	BBarclays	Equal Weight → Overweight	$10 → $17	+275.3%
Oct 20, 2023	Upgrade	CCitigroup	Sell → Neutral	$5 → $10	+120.8%
Sep 21, 2023	Initiated	BBarclays	Equal Weight	$10	+120.8%
Sep 07, 2022	Initiated	MMorgan Stanley	Equal-Weight	$10	+120.8%
Sep 06, 2022	Downgrade	CCitigroup	Buy → Sell	$12 → $5	+10.4%
Jul 26, 2022	Initiated	CCitigroup	Buy	$12	+164.9%

Today 07:00AM	Alvotech to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-28-26 07:00AM	Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 (GlobeNewswire)
Oct-20-26 05:22AM	Alvotech shares jump premarket after FDA approves new Simlandi process (Investing.com)
04:30AM	Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process That More Than Doubles Output Per Batch (GlobeNewswire)
Oct-14-26 04:30AM	Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea 8 mg (GlobeNewswire)
04:37PM	Loading…
Oct-06-26 04:37PM	Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply (GlobeNewswire)
Oct-05-26 03:14PM	Alvotech Soars 13% on FDA Nod That Effectively Doubles US Humira Biosimilar Capacity (TIKR) +12.11%
11:21AM	Alvotech stock surges after FDA manufacturing approval (Investing.com)
04:00AM	FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira (GlobeNewswire)
Sep-16-26 02:33PM	ALVO Stock Jumps On Double Upgrade Why Barclays Sees A 59% Upside (Stocktwits)
06:53AM	Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target (InvestorsHub)
Aug-31-26 04:30AM	Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio to Subcutaneous Presentations (GlobeNewswire)
Aug-27-26 08:00AM	Alvotech to present at upcoming investor conferences in September (GlobeNewswire)
Aug-24-26 06:41AM	BofA starts bullish Alvotech coverage on biosimilar launch cycle (Investing.com) +18.51%
Aug-21-26 09:00AM	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets (GlobeNewswire)
04:30PM	Loading…
Aug-19-26 04:30PM	Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update (GlobeNewswire) +7.02%
09:18AM	Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 461% Upside (GuruFocus.com)
Aug-18-26 09:18AM	Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 471% Upside (GuruFocus.com)
Aug-10-26 08:00AM	Alvotech to Report Financial Results for H1 2026 (GlobeNewswire)
Jul-29-26 09:32AM	Alvotech announces successful closure of FDA inspection of manufacturing facility (GlobeNewswire) +13.87%
Jul-03-26 04:01PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Jul-01-26 04:00AM	Alvotech further strengthens liquidity by securing term loan facility of $75 million (GlobeNewswire)
Jun-22-26 06:48PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire) -6.89%
Jun-18-26 05:51AM	Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement (GlobeNewswire)
04:00AM	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares (GlobeNewswire)
Jun-15-26 11:59PM	Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement (GlobeNewswire) -8.73%
04:01PM	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares (GlobeNewswire)
Jun-10-26 04:30PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Jun-08-26 06:41AM	Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO) (InvestorsHub) +19.77%
04:00AM	Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (GlobeNewswire)
04:00AM	Loading…
Jun-04-26 04:00AM	Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea (GlobeNewswire) +19.11%
Jun-03-26 04:30PM	Main Results of 2026 Annual and Extraordinary General Meeting (GlobeNewswire)
Jun-02-26 04:30PM	Alvotech to present at upcoming investor conferences in June (GlobeNewswire) -6.83%
Jun-01-26 04:30AM	Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland (GlobeNewswire)
May-11-26 04:30AM	Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility (GlobeNewswire) +10.12%
May-06-26 04:30PM	Alvotech Q1 2026 Financial Results (GlobeNewswire) -10.36%
09:27AM	Earnings To Watch: Alvotech (ALVO) Reports Q1 2026 Result (GuruFocus.com)
Apr-30-26 04:30PM	Alvotech Announces a Change in its Executive Team (GlobeNewswire)
Apr-24-26 08:30AM	Alvotech to Report Financial Results for the First Quarter of 2026 (GlobeNewswire)
Mar-30-26 07:58PM	Alvotech files Annual Report with the SEC (GlobeNewswire) +5.79%
07:55PM	Alvotech Publishes 2025 Annual Report (GlobeNewswire)
Mar-18-26 06:15PM	Alvotech Q4 2025 and Full Year 2025 Financial Results (GlobeNewswire) -5.79%
09:18AM	Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Mar-17-26 09:18AM	Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +5.82%
Mar-04-26 03:00AM	Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-26-26 04:00PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Feb-15-26 04:08AM	Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80 (Insider Monkey)
Feb-11-26 11:00AM	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire) -6.73%
Feb-05-26 03:00AM	Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio (GlobeNewswire)
Feb-04-26 01:39PM	Alvotech (ALVO): A Bull Case Theory (Insider Monkey)
Feb-02-26 03:00AM	Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates (GlobeNewswire)
Jan-29-26 03:00AM	Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg (GlobeNewswire)
Jan-22-26 09:26AM	Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y (Zacks)
Jan-16-26 08:52AM	ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? (Zacks)
Jan-09-26 03:16AM	Alvotech (ALVO) Secures $100 Million in New Financing (Insider Monkey)
Jan-07-26 05:00PM	Correction: Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Jan-06-26 03:00PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire) -6.53%
07:15AM	Alvotech announces planned CEO succession and leadership transition (GlobeNewswire)
Dec-31-25 04:30PM	Alvotech Secures Term Loan Facility of USD 100 Million (GlobeNewswire)
Dec-29-25 02:40PM	Changes in company's own shares (GlobeNewswire) -5.51%
Dec-22-25 03:26PM	Alvotech's Financial Calendar for 2026 (GlobeNewswire)
02:00AM	Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma (GlobeNewswire)
Dec-21-25 09:03AM	Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook (Insider Monkey)
Dec-19-25 03:30AM	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea (GlobeNewswire)
Dec-17-25 02:30AM	Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering (GlobeNewswire)
Dec-16-25 11:48AM	Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance (GlobeNewswire) -6.67%
Dec-11-25 09:30AM	Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman (PR Newswire)
Dec-05-25 05:06AM	New Strong Sell Stocks for Dec.5 (Zacks) +7.89%
Dec-04-25 01:39PM	Alvotech (ALVO): A Bull Case Theory (Insider Monkey) +9.27%
Dec-02-25 08:10PM	Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman (PR Newswire)
Nov-28-25 03:59AM	New Strong Sell Stocks for Nov. 28 (Zacks)
Nov-24-25 08:01PM	Alvotech (ALVO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Regulatory Challenges (GuruFocus.com) +6.42%
05:30AM	Alvotech Announces Approval of AVT03, a Biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area (GlobeNewswire)
Nov-21-25 05:27AM	New Strong Sell Stocks for Nov. 21st (Zacks)
05:10AM	Alvotech and Advanz announce EC approval for Gobivaz biosimilar (Pharmaceutical Business Review)
Nov-20-25 04:00AM	Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) (GlobeNewswire)
Nov-13-25 09:06AM	Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman (PR Newswire)
04:59AM	New Strong Sell Stocks for Nov. 13 (Zacks)
Nov-12-25 05:55PM	Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:40PM	Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update (GlobeNewswire)
07:20AM	Earnings To Watch: Alvotech (ALVO) Reports Q3 2025 Result (GuruFocus.com)
Nov-11-25 07:23AM	Alvotech (ALVO) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-10-25 04:00AM	UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea (aflibercept) (GlobeNewswire)
Nov-07-25 08:10AM	Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +12.85%
05:20AM	Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz (Pharmaceutical Business Review)
Nov-06-25 09:07AM	Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz, a Biosimilar to Simponi (golimumab), from the MHRA (GlobeNewswire)
08:30AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 10:00AM	Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:15AM	X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 04:01PM	Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update (GlobeNewswire)
02:00AM	Alvotech faces FDA setback for its Simponi biosimilar AVT05 (Pharmaceutical Technology)
Nov-02-25 05:12PM	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 (GlobeNewswire)
Oct-27-25 11:32AM	Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues (Zacks)
Oct-22-25 05:00AM	Alvotech Announces Changes in Global Business Development and Commercial Operations Team (GlobeNewswire)
Oct-21-25 03:53AM	Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength? (Zacks)
Oct-15-25 09:55AM	Wall Street Analysts See a 105.88% Upside in Alvotech (ALVO): Can the Stock Really Move This High? (Zacks) +5.65%
Oct-09-25 10:19AM	Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-06-25 08:00AM	Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR (omalizumab) (Business Wire)
04:40AM	European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency (GlobeNewswire)
Sep-30-25 09:15AM	Here's How Alvotech is Expanding its Portfolio Beyond Immunology (Zacks)

Show Previous News

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Founder & Executive ChairmanMr. Vilhelm Robert Wessman

Chief Executive OfficerMs. Lisa Graver

Chief Financial OfficerMs. Linda Jonsdottir

Chief Operating OfficerMr. Joseph E. McClellan

Chief Information OfficerMs. Neha Patel

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Alvotech

Upgrade your Finviz experience